DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
Completed · Phase 3 · NCT03523585
Conditions: Breast Cancer
At a glance
- Research payments reported, 2025
- $213,932
- U.S. investigators named
- 20
- Sites paid
- 18
- Planned or actual enrollment
- 608
About the trial
- Sponsor
- Daiichi Sankyo (with Daiichi Sankyo Co., Ltd., AstraZeneca)
- Tested
- Trastuzumab deruxtecan (drug), Capecitabine (drug), Lapatinib (drug), Trastuzumab (drug)
- Dates
- Started 2018-08-01; completion 2025-12-23
- Results posted
- Yes
This study will compare DS 8201a to standard treatment. Participants must have HER2 breast cancer that has been treated before. Their cancer: * cannot be removed by an operation * has spread to other parts of the body
From ClinicalTrials.gov, last updated 2026-02-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $213,932 in research payments for this study in 2025 (117 payments).
Products named: Enhertu
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Jennifer Fisher, M.D. Hematology & Oncology · San Diego, CA
- Omkar S. Marathe, MD Hematology & Oncology · Lakewood, CA
- Nicholas Mcandrew, M.D. Hematology & Oncology · Los Angeles, CA
- Ian E. Krop, MD PHD Medical Oncology · New Haven, CT
- Maryam B. Lustberg, M.D. Medical Oncology · New Haven, CT
- Christopher M. Gallagher, M.D. Hematology & Oncology · Washington, DC
- Grace Wang, M.D. Hematology & Oncology · Miami, FL
- Rajni Sinha, M.D. Hematology & Oncology · Atlanta, GA
- Jami Fukui, MD Medical Oncology · Honolulu, HI
- Haythem Y. Ali, M.D. Medical Oncology · Detroit, MI
- Ashley E. Frith, MD Medical Oncology · Saint Peters, MO
- Nicole O. Williams, M.D. Medical Oncology · Columbus, OH
- Adam M. Brufsky, MD Specialist · Pittsburgh, PA
- David M. Mintzer, MD Hematology & Oncology · Philadelphia, PA
- Jane M. Raymond, MD Medical Oncology · Pittsburgh, PA
- Brooke E. Daniel, MD Hematology & Oncology · Chattanooga, TN
- Erika P. Hamilton, M.D. Hematology & Oncology · Nashville, TN
- Gregory Vidal, M.D Medical Oncology · Germantown, TN
- Polly Niravath, MD Internal Medicine · Houston, TX
- Anuradha A. Belur, M.D Hematology & Oncology · Auburn, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ronald Reagan UCLA Medical Center, CA $51,517
- Medstar Health Research Institute $43,750
- Sharp Memorial Hospital $24,683
- Piedmont Hospital, Inc, GA $21,331
- Ohio State University $13,731
- Hospital of Univ of Pennsylvania, PA $12,344
- Washington University $11,263
- Dana-Farber Cancer Institute $9,230
- Sarah Cannon Research Institute $7,267
- West Kendall Baptist Hospital, FL $7,220
- West Cancer Center and Research Institute-East Campus $4,100
- Henry Ford Health Hospital, MI $3,071
- Allegheny Singer Research Institute $1,816
- Straub Clinic and Hospital, HI $756
- Toi Clinical Research $641
- The Methodist Hospital Research Institute $580
- Deaconess Medical Center, WA $550
- UPMC Hillman Cancer Center $85
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.